June 13, 2012 (Boston, Massachusetts) — The investigational dual orexin receptor antagonist suvorexant (Merck) improved sleep onset and maintenance over a 3-month treatment period in 2 pivotal phase 3 ...

TOKYO, May 28, 2025 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in ...

May 26 (UPI) --Researchers at Mount Sinai School of Medicine say a new study shows how a treatment commonly used for insomnia can assist in calming a potentially violent sleeping disorder in which ...

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with ...

TOKYO, Sept. 3, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will deliver a total of 11 presentations, including clinical data ...

Indivior has paid 15.95 million pounds sterling ($20.4 million) to C4X Discovery for the full rights to the British biotech’s orexin-1 receptor antagonist being developed for substance use disorder.

Idorsia is a Swiss biopharmaceutical company with multiple commercial and pre-commercial assets. Idorisa's lead asset Daridorexant seems to be a more attractive option compared to SOC in Isomnia due ...

While the study only involved narcolepsy type 1, previous work has shown that orexin signaling may be deficient in other ...

Tsukuba, Japan—Orexin, named after its role in feeding regulation, is a potent endogenous sleep/wake state regulator and is expected to play an essential role in controlling the cross-talk mechanism ...

ZURICH, Sept 2 (Reuters) - Swiss biotech firm Actelion's experimental sleep drug, the first of a new class of potential medicines, significantly improved sleep for insomniacs in mid-stage clinical ...